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Chemotherapy in the Elderly
 
To the Editor:
 
 Sargent et al. (Oct. 11 issue)
 
1
 
 report that
adjuvant chemotherapy with fluorouracil is as effective in
older patients with resected colon cancer as it is in younger
patients. Their conclusion is based on the absence of a sta-
tistically significant interaction between age and treatment
effect for both overall and disease-free survival. However,
the survival curves for treated and untreated patients who
were more than 70 years old seem closer than the curves
for treated and untreated younger patients. In our opinion,
the absolute gain in survival is the measure that should be
discussed with patients when deciding whether to use an
adjuvant treatment. We suspect that the absolute differences
in the study by Sargent et al. were small, and we would
like to know what the absolute gain in survival was at each
year of follow-up.
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To the Editor:
 
 Sargent et al. conclude that “it is reason-
able to consider chemotherapy in nearly all patients with
resected stage II and stage III colon cancer.” But the idea
that adjuvant therapy is beneficial for patients with stage
II colon cancer is not supported by the data. Patients with
stage II disease and those with stage III disease do not
have the same rate of survival at five years. Indeed, the rate
of overall survival among patients with stage II disease may
be as high as 78 percent, and elderly patients included in a
trial may have rates of overall survival that exceed those in
an age- and sex-matched population of persons without
cancer.
 
1,2
 
The flaws of the studies on which the authors base their
meta-analysis are in part responsible for this conclusion,
since many of the studies have grouped patients with stage
II disease and those with stage III disease together, as if
the characteristics of the two stages were similar. The con-
clusion that adjuvant therapy can be safely given to elderly
persons is welcome news for patients with stage III disease.
To advocate such treatment for patients with stage II dis-
ease is to include a large group of patients who have a high
rate of survival with surgery alone, exposing particularly
those who are elderly only to the side effects of the treat-
ment, not to the survival benefit.
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To the Editor:
 
 Sargent et al. state that elderly persons re-
ceive adjuvant chemotherapy less frequently than younger
patients, citing rates of chemotherapy use from a study that
linked 1992 data from the Surveillance, Epidemiology, and
End Results (SEER) Program with Medicare data for 1992.
 
1
 
However, two more recent studies of SEER–Medicare
data report rates of use of adjuvant chemotherapy among
elderly persons with stage III colon cancer that are con-
siderably higher than the rates reported by Sargent et al.
 
2,3
 
With the use of data from 1992 to 1996, these studies
showed that the rate of adjuvant-chemotherapy use was
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higher than 73 percent among persons who were 65 to 69
years old and was higher than 68 percent among those who
were 70 to 74. According to one of these studies, by 1996,
the rate of adjuvant-chemotherapy use was 81 percent
among persons who were 65 to 74 years old.
 
2 
 
This rate is
about 70 percent higher than that reported by Sargent et
al. An analysis of adjuvant-treatment rates based on med-
ical records for persons of all ages who received a diagnosis
of stage III colon cancer in 1990, 1991, or 1995 showed
that the rate of use of fluorouracil was 74 percent among
persons under the age of 55 years, 71 percent among those
who were 55 to 64 years old, and 67 percent among those
who were 65 to 74 years old (Potosky A, National Cancer
Institute: personal communication).
The more recent estimates should be used as the bench-
mark for chemotherapy use in the elderly. In addition, rates
of adjuvant-chemotherapy use for persons who are 65 to
74 years old do not appear to be markedly lower than those
for persons who are 55 to 64. These findings suggest that age
may not greatly influence clinicians’ decisions about treat-
ment for “young old” persons with stage III colon cancer.
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The authors reply:
 
To the Editor:
 
 Perrone et al. have requested the absolute
differences between survival rates among treated and un-
treated patients, according to the age group. Because there
was no interaction between age and treatment, we believe
that the data we initially presented — the five-year survival
rates of 71 percent for treated patients and 64 percent for
untreated patients — represent the most appropriate and
reliable measure of the absolute benefit for both age groups
(«70 years and >70 years). As shown in Table 1, the age-
specific rates for each year of follow-up are very similar for
the two age groups in terms of the absolute benefit of treat-
ment; among patients who were 70 years of age or young-
er, the rate of overall survival at five years was 71 percent
for treated patients, as compared with 64 percent for un-
treated patients; among those over the age of 70, the five-
year rates of overall survival were 69 percent for treated
patients and 62 percent for untreated patients.
We agree with Nauta that the benefit of adjuvant treat-
ment for patients with stage II cancer is controversial, with
different groups of investigators drawing different conclu-
sions.
 
1,2
 
 Our intention was to honor the initial randomiza-
tion used in each study included in our pooled analysis;
each of these studies included both patients with stage II
disease and those with stage III disease in the initial ran-
domization. In the community, adjuvant treatment of pa-
tients with stage II cancer is common, with 31 percent of
Medicare-age patients who have stage II disease receiving
adjuvant therapy.
 
3
 
 We support the current U.S. intergroup
strategy of mounting separate trials for stage II disease and
for stage III disease. In addition, stratification of patients
into high-risk and low-risk groups on the basis of molec-
ular markers such as microsatellite instability may eventu-
ally prove to be a clinically useful decision-making tool.
Regarding the frequency of chemotherapy in patients
with stage III cancer who are 65 to 74 years old, it is indeed
promising news that the use of therapy in such patients is in-
creasing, as Warren and Brown note. However, both reports
that they cite
 
4,5
 
 conclude that age continues to be a strong
predictor of chemotherapy use and that further efforts are
needed to ensure that elderly patients and their physicians
have full information and receive appropriate treatment.
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Tuberculosis and Treatment with Infliximab
 
To the Editor:
 
 In support of the findings of Keane et al.
(Oct. 11 issue),
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 we describe the reactivation of latent tu-
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1 93 92 96 95
2 85 84 88 85
3 79 76 81 76
4 72 68 76 69
5 69 62 71 64
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
 624
 
·
 
N Engl J Med, Vol. 346, No. 8
 
·
 
February 21, 2002
 
·
 
www.nejm.org
 
The New England Journal  of  Medicine
berculosis in a 19-year-old Pakistani man treated with in-
fliximab for sight-threatening uveitis of unknown cause
despite extensive investigation. The patient presented with
a 3-week history of fever, sweats, dry cough, and breath-
lessness 60 days after the first of three intravenous boluses
of infliximab at a dose of 5 mg per kilogram of body weight.
Upper and midzone interstitial lung shadowing and exten-
sive lymphadenopathy were noted on computed tomograph-
ic scanning. Lymph-node biopsy revealed heavy infiltration
with acid-fast bacilli. The patient’s symptoms improved after
the initiation of treatment with rifampin, pyrazinamide, and
isoniazid, but his temperature continued to spike (39.5°C)
for a further six weeks. Immune-function testing demon-
strated that his T cells were able to make interferon-
 
g
 
 in re-
sponse to stimulation with purified protein derivative. No
other immunodeficiency was noted.
Twenty months earlier, the patient had been screened ac-
cording to the guidelines of the British Thoracic Society
 
2
 
 as
a close contact of a patient with smear-positive pulmonary
tuberculosis and deemed not to be infected. A grade 2 re-
sponse to a Heaf test at the time was thought to be con-
sistent with prior bacille Calmette–Guérin vaccination. The
timing of events, extent of disease, and clinical course de-
scribed are all consistent with an association between in-
fliximab and the reactivation of tuberculosis.
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To the Editor:
 
 Keane et al. reported that active tubercu-
losis may develop soon after the initiation of treatment
with infliximab. We describe a case of disseminated histo-
plasmosis after similar treatment.
A 19-year-old man had Crohn’s disease (diagnosed at
the age of 12 years) that was not controlled by conventional
treatment. While still receiving mercaptopurine he was giv-
en infliximab (5 mg per kilogram) in June 2000. Symptoms
of Crohn’s disease improved, and a second dose of inflix-
imab was given in September 2000. Three weeks later he
presented with fever (temperature, 40.0°C), followed over
the next four weeks by a nonproductive cough, abdominal
discomfort, watery stools, and massive hepatosplenomeg-
aly, with progressive leukopenia (cell count, 2.31¬10
 
9
 
 per
liter) and thrombocytopenia (cell count, 79¬10
 
9
 
 per liter).
A workup revealed no evidence of active Crohn’s disease, a
malignant condition, tuberculosis, or infection with Ep-
stein–Barr virus, cytomegalovirus, or bacteria. Histopath-
ological examination of biopsy specimens of the colon, liv-
er, and bone marrow showed noncaseating granulomas.
Fungus-like organisms were detected within the granulomas,
and cultures were positive for 
 
Histoplasma capsulatum.
 
 Ther-
apy with amphotericin B (15 mg per kilogram) was admin-
istered, followed by itraconazole (200 mg per day). The pa-
tient recovered uneventfully.
The patient had grown up in Louisiana and had attended
college in Ohio, areas where histoplasmosis is endemic.
This fact and the short interval between the infliximab in-
fusion and the appearance of symptoms suggest that our
patient had a reactivation of prior infection.
Tumor necrosis factor 
 
a
 
 (TNF-
 
a
 
) is an important immune
modulator, and neutralization of this cytokine significantly
suppresses the immune response. Inhibition of TNF-
 
a
 
 re-
sulted in delayed clearance of 
 
Pneumocystis carinii
 
 in the
lungs of immunocompetent mice.
 
1
 
 Blockade of TNF-
 
a
 
 ex-
acerbated chronic infection in CD4+ cell–depleted mice.
In addition to neutralizing secreted TNF-
 
a
 
, infliximab ex-
erts an immunosuppressive effect by attacking immune ef-
fector cells that express membrane-bound TNF-
 
a
 
,
 
2
 
 fur-
ther impairing host defenses.
Z
 
ILI
 
 Z
 
HANG
 
, M.D., P
 
H
 
.D.
H
 
ERNÁN
 
 C
 
ORREA
 
, M.D.
R
 
ODOLFO
 
 E. B
 
ÉGUÉ
 
, M.D.
 
Louisiana State University Health Sciences Center
New Orleans, LA 70112
rbegue@lsuhsc.edu
 
1.
 
Kolls JK, Lei D, Vasquez C, et al. Exacerbation of murine 
 
Pneumocystis 
carinii
 
 infection by adenoviral-mediated gene transfer of a TNF inhibitor. 
Am J Respir Cell Mol Biol 1997;16:112-8.
 
2.
 
Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-
TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane 
TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
 
To the Editor:
 
 Keane et al. report that tuberculosis de-
veloped in some patients with Crohn’s disease or rheuma-
toid arthritis after treatment with infliximab. We believe
that these patients need to be described separately, espe-
cially with respect to their clinical characteristics and the
interval between infliximab treatment and the appearance
of tuberculosis. There is a possibility that some patients who
have been given a diagnosis of Crohn’s disease actually have
abdominal tuberculosis. Both conditions can present with
transmural spread and penetration through the muscle coat,
although this presentation is relatively less common in
Crohn’s disease. These conditions have a similar microscop-
ic appearance that includes granulomas, and the caseation
that is characteristic of tuberculosis is often difficult to iden-
tify.
 
1
 
 In areas where abdominal tuberculosis is more fre-
quent, some criteria must be fulfilled to differentiate intestin-
al tuberculosis from Crohn’s disease: there must be histologic
evidence of tubercles with caseation necrosis; there must
be a good typical gross description of operative findings,
with biopsy of mesenteric nodes showing histologic evi-
dence of tuberculosis; inoculation into animals or culture
of the suspected tissue must result in the growth of tuber-
cle bacilli; and histologic examination must show 
 
Mycobac-
terium tuberculosis
 
 in a lesion.2 In an urban British popu-
lation with a large number of Asian immigrants, abdominal
tuberculosis was not infrequent, whereas Crohn’s disease
occurred rarely in Asian immigrants.3 A clear distinction
in describing the general characteristics of patients with
Crohn’s disease and rheumatoid arthritis in whom tuber-
culosis developed will be useful, given that when we diag-
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nose Crohn’s disease we are at risk of underdiagnosing ab-
dominal tuberculosis.
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STEFANO BONORA, M.D.
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terology. 2nd ed. Vol. 2. Philadelphia: W.B. Saunders, 1964:311-34.
3. Palmer KR, Patil DH, Basran GS, Riordan JF, Silk DBA. Abdominal tu-
berculosis in urban Britain — a common disease. Gut 1985;26:1296-305.
To the Editor: Keane et al. describe the occurrence of ac-
tive tuberculosis soon after the initiation of treatment with
infliximab. We describe a nine-year-old girl with classic sys-
temic-onset juvenile idiopathic arthritis,1 who was given a
diagnosis of osteoarticular tuberculosis shortly after com-
mencing treatment with etanercept. She had been treated
with corticosteroids (initially intravenous methylpredniso-
lone, then oral corticosteroids) and methotrexate. However,
owing to poor control of the disease, etanercept (0.4 mg
per kilogram) was substituted for methotrexate, with a good
response initially (the active-joint count and levels of acute-
phase reactants were decreased and her sense of well-being
improved). Five weeks later, a painful swollen left ankle de-
veloped, but the patient remained well and afebrile. Clear
synovial fluid was aspirated from the joint (which was ster-
ile on routine culture). Etanercept was recommenced, and
she remained well. However, three weeks later M. tuberculosis
complex was isolated, and its identity was confirmed by a
gene probe; it then was found to be a fully sensitive strain
of M. tuberculosis. An isotopic bone scan revealed additional
sites of presumed infection, but the chest radiograph was
normal. Tracing of the patient’s contacts identified no source
of infection. Etanercept was stopped. Antituberculosis treat-
ment included standard triple therapy, extended for 12
months, with rifampin and isoniazid continued as mainte-
nance therapy, since the reactivation of systemic juvenile id-
iopathic arthritis necessitated the resumption of methotrex-
ate therapy. She continues to take corticosteroids (<0.5
mg per kilogram every other day), and 18 months later,
she is well and her arthritis is clinically inactive.
Osteoarticular tuberculosis is uncommon in children in
Britain. Tuberculosis should be considered in immunocom-
promised patients, especially those with monoarthropathy,
and in patients who have received anti-TNF therapy, since
such therapy may suppress the classic signs of infection.
ANDREA MYERS, M.B., CH.B.
University of Newcastle upon Tyne
Newcastle upon Tyne NE2 4HH, United Kingdom
andrea.myers@ncl.ac.uk
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Newcastle upon Tyne NE2 4HH, United Kingdom
1. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed clas-
sification criteria for juvenile idiopathic arthritis: Durban, 97. J Rheumatol 
1998;25:1991-4.
To the Editor: Study of animal models has provided a
guide to the safety of the inhibition of TNF in humans,
including its effect on susceptibility to tuberculosis.1,2 The
report by Keane and colleagues highlights important safety
concerns regarding the reactivation of tuberculosis in re-
cipients of TNF inhibitors, but we found that the absence
of TNF had no adverse effect on morbidity or overall sur-
vival in TNF-deficient mice that had not previously been
exposed to M. tuberculosis.
We conducted a prospective age- and sex-matched 30-
month study of morbidity and mortality in a cohort of
106 wild-type C57BL/6 mice and 98 C57BL/6 mice ren-
dered TNF-deficient by gene targeting (Riminton DS, et
al., unpublished data). The cohorts were divided into two
groups: one housed under pathogen-free conditions and the
other under conventional conditions. Survival of TNF-defi-
cient mice was equivalent to that of controls (P=0.9 by the
log-rank test; hazard ratio, 1.02; 95 percent confidence in-
terval, 0.66 to 1.6), irrespective of environmental variations.
The same TNF-deficient mice, however, had greatly in-
creased susceptibility to disease on inhalational challenge
with virulent M. tuberculosis.2
SEAN RIMINTON, M.B., CH.B., PH.D.
NICHOLAS PEARCE, PH.D.
ANTONY BASTEN, M.B., B.S., D.PHIL.
Centenary Institute of Cancer Medicine and Cell Biology
Sydney, NSW 2050, Australia
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1. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is 
required in the protective immune response against Mycobacterium tuber-
culosis in mice. Immunity 1995;2:561-72.
2. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in gran-
uloma formation in TNF gene-targeted mice underlie the heightened sus-
ceptibility to aerosol Mycobacterium tuberculosis infection, which is not 
compensated for by lymphotoxin. J Immunol 1999;162:3504-11.
The authors reply:
To the Editor: The findings of Lim et al. support our
finding of an association between infliximab and tubercu-
losis. Since our report was published, the Food and Drug
Administration (FDA) has received 47 additional reports
of infliximab-associated tuberculosis, for a total of 117 cas-
es through November 30, 2001. Given that the amount of
underreporting is unknown, the estimated rate of tuber-
culosis reported to the FDA for the first year of treatment
with infliximab is approximately 41 per 100,000 in U.S.
patients with rheumatoid arthritis, 9 per 100,000 in U.S.
patients with Crohn’s disease, and 224 per 100,000 in all
non-U.S. patients with rheumatoid arthritis or Crohn’s dis-
ease. The infliximab package insert states that screening for
and treatment of latent tuberculosis are indicated before the
drug is prescribed.1 This precaution is important because
cases of tuberculosis influence public health as well as the
health of the patient. Our data do not rule out an associ-
ation between etanercept and tuberculosis, and the case re-
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ported by Myers et al. highlights the need for continued sur-
veillance for tuberculosis with the use of all anti-TNF agents.
The case reported by Zhang et al. of histoplasmosis in
association with infliximab emphasizes the possibility that
infections that are dormant in granulomas may become
susceptible to reactivation when TNF is neutralized. Of the
11 cases of histoplasmosis after infliximab that have been
reported to the FDA, 10 required care in the intensive care
unit and 1 was fatal. This experience highlights the impor-
tance of the early diagnosis and treatment of histoplasmosis.
We acknowledge the difficulty in differentiating Crohn’s
disease from enteric tuberculosis, as mentioned by De Rosa
et al. Indeed, mycobacterial infection has been suggested
as a possible etiologic agent of Crohn’s disease.2 To date,
27 cases of tuberculosis have been reported in patients with
Crohn’s disease after treatment with infliximab for a me-
dian of 10 weeks (range, 4 to 52). Sixteen of these patients
had extrapulmonary disease, and five had disseminated tu-
berculosis. In our study, one patient who was initially con-
sidered to have Crohn’s disease was reclassified as having
enteric tuberculosis and was excluded from the analysis.
Available data suggest that these cases of tuberculosis were
not from an otherwise high-risk group, such as inner-city
Asian immigrants. The possibility of occasional mistaken
diagnoses does not detract from the importance of testing
for tuberculosis infection in patients with Crohn’s disease
before the initiation of infliximab therapy.
The immunologic events that explain the possible link
between blockade of TNF and the failure of granuloma to
contain bacilli are poorly understood. We have seen an in-
terferon-g–independent mycobactericidal effect of macro-
phages that is mediated by host-cell apoptosis and depend-
ent on TNF.3 Consistent with this finding is the report of
Lim et al. that the secretion of IFN-g by T cells was normal
after stimulation with purified protein derivative in their pa-
tient who was receiving infliximab. Bean et al. have demon-
strated normal T-cell activation in tuberculosis-infected mice
that have a disruption of the TNF gene.4 Given the pleio-
tropic nature of TNF, it most likely influences many aspects
of the immune response to tuberculosis.
JOSEPH KEANE, M.D.
Boston University School of Medicine
Boston, MA 02118
jkeane@lung.bumc.bu.edu
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3. Keane J, Shurtleff B, Kornfeld H. TNF-dependent BALB/c murine 
macrophage apoptosis following Mycobacterium tuberculosis infection in-
hibits bacillary growth in an IFN-gamma independent manner. Tuberculo-
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Lack of Health Insurance and Overall Health
To the Editor: Baker et al. (Oct. 11 issue)1 used disability
data from the 1992 and 1996 surveys of the Health and
Retirement Study to assess the effect of health insurance
status on the risk of the development of a physical disability.
Unfortunately, as pointed out in the article, the wording of
the questions related to disability on the Health and Re-
tirement Study surveys changed between 1992 and 1996.
The initial survey, in 1992, inquired about the perform-
ance of physical tasks. The wording was, “How difficult is it
for you to [perform this task]?” and the potential answers
were “not at all difficult,” “a little difficult,” “somewhat dif-
ficult,” “very difficult,” and “something you can’t do at all.”
In 1994, subjects were asked about the same tasks, but the
question was changed to, “Do you have any difficulty with
[this task]?” Subjects who reported difficulty were asked,
“Is that a little or a lot of difficulty?” In 1996, the ques-
tion was changed again and became, “Because of a health
problem do you have any difficulty with [this task]?” The re-
sponses (“yes,” “no,” “can’t do,” or “don’t do”) were re-
corded for the same tasks as in the previous surveys.
To deal with these changes in format, Baker et al. restrict-
ed their analyses to participants who reported a new dis-
ability in 1996. They made the assumption that participants
who answered “not at all difficult” in 1992 and then either
“yes” or “can’t do” in 1996 had a new disability. We exam-
ined the effect the wording change may have had on the
outcome by using an experimental module from the 1994
survey in which 771 subjects were asked questions about
disability in both the 1992 and the 1994 formats. Since the
first part of the 1994 question format is almost identical to
the 1996 format, we were able to compare the participants’
responses to the old (1992) and new (1996) questions.
We used the algorithm described by Baker et al. to de-
termine the number of participants in whom a new mo-
bility- or agility-related disability would appear to have de-
veloped solely on the basis of the change in the question
(Table 1). We found that 14 percent of the subjects would
appear to have a new agility-related disability but that only
4 percent would appear to have a new mobility-related dis-
ability. Baker et al. reported that 17.1 percent of the contin-
uously insured participants and 28.8 percent of the contin-
uously uninsured participants had a new disability related to
mobility (P<0.001) and that 32.2 percent and 38.7 per-
cent, respectively, had a new agility-related disability (P=
0.003). The lack of concordance with the results from the
TABLE 1. PARTICIPANTS WHO REPORTED A NEW 
DISABILITY IN MOBILITY OR AGILITY IN 1994 
AS A RESULT OF THE CHANGE IN QUESTION FORMAT.
NEW DISABILITY MOBILITY AGILITY
no. (%)
No 663 (95.7) 617 (85.9)
Yes 30 (4.3) 101 (14.1)
Total 693 718
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
CORRESPONDENCE
N Engl J Med, Vol. 346, No. 8 · February 21, 2002 · www.nejm.org · 627
experimental module suggests that some of the differences
between the insured and uninsured participants may have
reflected the change in question format.
It is not our intention to suggest that health insurance
status does not have an important effect on health status
and disability status. However, because of the change in
question format in these surveys, it is difficult to determine
the magnitude of the effect from the data used in the analy-
sis. Repeating the analysis with data from 1996 through
2000 would allow the authors to estimate the true effect of
insurance on disability with the use of identically worded
questions.
DAVID J. HARRISON, M.A.
ANDREA K. BIDDLE, M.P.H., PH.D.
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7411
davidharrison99@hotmail.com
1. Baker DW, Sudano JJ, Albert JM, Borawski EA, Dor A. Lack of health 
insurance and decline in overall health in late middle age. N Engl J Med 
2001;345:1106-12.
The authors reply:
To the Editor: Harrison and Biddle present data suggest-
ing that changes in the questions about physical function-
ing in the Health and Retirement Study could have led us
to overestimate the rate at which new physical difficulties
developed in the participants. They used an “experimental
module” from the main 1994 interview as their gold stand-
ard to judge the validity of the measured outcomes. This
approach is problematic, because although the questions in
the experimental module were identical to the questions ad-
ministered at base line (1992), the mode of administration
was different (a face-to-face interview in 1992 in contrast
to a self-administered questionnaire in the experimental
module in 1994). It is therefore uncertain that the exper-
imental module provides the most valid estimate of the rate
of new physical difficulties. Moreover, we measured out-
comes with data from the 1996 questions, not the 1994
questions used in the analysis conducted by Harrison and
Biddle. It is unclear whether their results can be general-
ized to the 1996 data, because the 1996 questions had a
different set of response options than either the 1992 or
the 1994 questions.
It remains possible that changes in the survey questions
may have led us to overestimate the true number of per-
sons in whom new difficulties developed, particularly with
respect to agility. However, we disagree that the “differences
between the insured and uninsured participants may have
reflected the change in question format.” This would be
true only if any misclassification of the outcomes was larger
among the uninsured participants than among the insured
participants (i.e., if there was differential misclassification bi-
as),1 and Harrison and Biddle do not present evidence sug-
gesting such a bias. In general, unbiased error in the meas-
urement of an outcome leads to underestimation of the
true difference between groups (i.e., a bias toward the
null).1 For example, we reported that the rate of new mo-
bility difficulties was 17.1 percent among the continuously
insured participants and 28.8 percent among those who
were continuously uninsured. If both of these figures were
overestimated by 4 percentage points, then the true rates of
new difficulties with mobility would be 13.1 percent and
24.8 percent, respectively. Thus, the correct estimate of the
crude relative risk of new mobility difficulties among the
continuously uninsured participants as compared with those
who were continuously insured would be 1.89, which is
substantially higher than our original estimate of 1.68.
Therefore, our findings may have underestimated the in-
creased risk of a decline in physical functioning in uninsured
persons. We agree that it is important to examine whether
the uninsured participants were at increased risk for the de-
velopment of new physical difficulty between 1996 and
2000, a period when the questions about physical function-
ing in the Health and Retirement Study remained the same.
DAVID W. BAKER, M.D., M.P.H.
JOSEPH J. SUDANO, PH.D.
MetroHealth Medical Center
Cleveland, OH 44109-1998
dwb@po.cwru.edu
1. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: 
principles and quantitative methods. New York: Van Nostrand Reinhold, 
1982.
Research in Developing Countries
To the Editor: Shapiro and Meslin1 and Koski and Night-
ingale2 (July 12 issue) discuss the ethical problems that oc-
cur when developed countries sponsor clinical trials in de-
*The United Nations has set a target of 0.70 percent of
the gross domestic product (GDP).
TABLE 1. OVERSEAS-DEVELOPMENT AID IN 1999.*
COUNTRY AID
% of GDP $U.S. (billions)
Denmark 1.01 1.73
Norway 0.91 1.37
The Netherlands 0.79 3.13
Sweden 0.70 1.63
Luxembourg 0.66 0.12
France 0.39 5.64
Switzerland 0.35 0.97
Japan 0.35 15.32
Finland 0.33 0.42
Ireland 0.31 0.25
Belgium 0.30 0.76
Canada 0.28 1.70
New Zealand 0.26 0.13
Germany 0.26 5.52
Austria 0.26 0.53
Portugal 0.26 0.28
Australia 0.26 0.98
United Kingdom 0.23 3.40
Spain 0.23 1.36
Greece 0.15 0.19
Italy 0.15 1.81
United States 0.10 9.15
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veloping countries. Many of the ethical problems arise
because developing countries are poor and cannot afford
the treatments that are used in developed countries. An
important ethical issue is therefore the amount of economic
aid given by rich countries to poor countries.
The total amount of aid given to developing countries
has decreased substantially over the past 10 years. The Unit-
ed States, in particular, now gives a much lower proportion
of the gross domestic product (GDP) than any other coun-
try that belongs to the Organization for Economic Coop-
eration and Development (OECD) (and my country, Aus-
tralia, also gives less than the average amount). Table 1
shows the amount of aid given by each OECD country,
with the least generous nations at the bottom of the table.3
The target for overseas-development aid that has been es-
tablished by the United Nations is 0.7 percent of the GDP;
only Denmark, Norway, the Netherlands, and Sweden meet
or exceed this amount.
Perhaps doctors in developed countries could do more
to persuade their governments to help developing coun-
tries. This would reduce the large disparity in wealth that
is the root cause of the ethical problems that arise when
clinical trials sponsored by developed countries are con-
ducted in developing countries.
FRANK SHANN, M.B., M.D.
Royal Children’s Hospital
Melbourne, VIC 3052, Australia
shannf@cryptic.rch.unimelb.edu.au
1. Shapiro HT, Meslin EM. Ethical issues in the design and conduct of 
clinical trials in developing countries. N Engl J Med 2001;345:139-42.
2. Koski G, Nightingale SL. Research involving human subjects in devel-
oping countries. N Engl J Med 2001;345:136-8.
3. Important DAC statistical tables and charts: table: total ODA flows in 
1998 and 1999. Paris: Organization for Economic Cooperation and De-
velopment. (Accessed February 4, 2002, at http://www.oecd.org/dac/
htm/dacstats.htm#dactables.)
To the Editor: As chairman of the investigational review
board at my institution, I believe the use of a placebo by
a U.S. organization administering a clinical trial in a devel-
oping country, when the same study performed here would
demand a therapeutic control, should be viewed with skep-
ticism. Use of placebo on the grounds that one cannot de-
termine the best alternative to the treatment under investi-
gation or, worse, on the grounds that such use is consistent
with the local standard of care — no therapy — is poten-
tially inhumane, even if people are no worse off at the end
of the study than they would have been if they had not
participated in it.
Conducting a placebo-controlled trial when there is a rea-
sonable therapeutic alternative to the treatment under inves-
tigation is most likely to be motivated by financial consider-
ations. In the United States, we have categorically rejected
the notion of children working in sweatshops to make cloth-
ing. How can we accept the possibility of using drugs that
have been tested in trials in underdeveloped countries in
which patients in control groups may have suffered or died
because they received placebo instead of active treatment?
STEVEN D. SCHWAITZBERG, M.D.
New England Medical Center
Boston, MA 02021
sschwaitzberg@lifespan.org
Nongenetic Male Pseudohermaphroditism
To the Editor: Mendonca et al. (Oct. 11 issue)1 conclude
that the finding of discordance in growth and genital de-
velopment in monozygotic twins “convincingly” rules out
a genetic cause of male pseudohermaphroditism. There
are known genetic mechanisms that could account for the
discordance. Fourteen cases of discordance in monozygot-
ic twins have been reported in Beckwith–Wiedemann syn-
drome.2,3 Alternatively, a nondisjunction or reduplication
event at the time of the first cell division could result in
uniparental disomy of a chromosome (i.e., both chromo-
somes are inherited from either the father or the mother).
Maternal uniparental disomy of chromosome 7 has been
associated with the Silver–Russell syndrome, which results
in decreased weight gain and linear growth, whereas the
paternal form has no discernible phenotype. Hypospadias
has been reported in Silver–Russell syndrome.4 One chro-
mosome 7 marker was tested, but it did not provide infor-
mation that would rule out whole-chromosome uniparental
disomy, nor would testing a single chromosome 7 marker
rule out segmental disomy due to a somatic recombination
involving chromosome 7 homologues before the first cell
division, an event that could also result in the same pheno-
type. Maternal uniparental disomy of chromosome 14 is also
associated with growth retardation and genital anomalies.5
All of these are disorders of imprinting and gene expres-
sion (sometimes referred to as epigenetic effects). The lim-
ited panel of markers tested to confirm monozygosity in the
case described by Mendonca et al. does not rule out uni-
parental disomy. 
The occurrence of a somatic mutation in the affected male
twin after the first cell division would be a second potential
explanation. This event would result in discordance for a
genetic condition. Although the authors may be correct
that there are nongenetic causes of this phenotype, to rule
out genetic conditions on the basis of the evaluation they
describe is not justified.
MARC S. WILLIAMS, M.D.
Gundersen Lutheran Medical Center
LaCrosse, WI 54601
mwilliam@gundluth.org
1. Mendonca BB, Billerbeck AEC, de Zegher F. Nongenetic male pseudo-
hermaphroditism and reduced prenatal growth. N Engl J Med 2001;345:
1135.
2. Elliott M, Maher ER. Beckwith-Wiedemann syndrome. J Med Genet 
1994;31:560-4.
3. Orstavik RE, Tommerup N, Eiklid K, Orstavik KH. Non-random 
X chromosome inactivation in an affected twin in a monozygotic twin pair 
discordant for Wiedemann-Beckwith syndrome. Am J Med Genet 1995;
56:210-4.
4. Jones KL. Smith’s recognizable patterns of human malformation. 5th 
ed. Philadelphia: W.B. Saunders, 1997:96-9.
5. Sutton VR, Shaffer LG. Search for imprinted regions on chromosome 
14: comparison of maternal and paternal UPD cases with cases of chromo-
some 14 deletion. Am J Med Genet 2000;93:381-7.
The authors reply:
To the Editor: We thank Dr. Williams for explicitly stat-
ing some of the hypotheses to which we referred in our
report but which were not formally excluded because we
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had no plausible clinical basis to do so. We described mono-
zygotic boys, one of whom had reduced prenatal growth,
male pseudohermaphroditism, and no other anomalies;
there was no clinical evidence of Beckwith–Wiedemann,
Silver–Russell, or other syndromes. So far, this constella-
tion has not been observed in children with uniparental
disomy of chromosome 7 or 14 (or of chromosome 2, 9,
11, 16, or 20); conversely, the exclusive combination of
prenatal growth retardation and incomplete male differen-
tiation — which is not rare — has hitherto not been ascribed
to uniparental disomy. Nevertheless, we have now tested the
hypothesis that these anomalies were due to uniparental di-
somy of chromosome 7 or 14 by assessing five markers along
chromosome 7 (D7S507, D7S484, D7S519, D7S630, and
D7S661) in addition to the previously studied D7S820 and
three markers along chromosome 14 (D14S70, D14S258,
and D14S280), using an ABI Prism Linkage Mapping Set
(Applied Biosystems, Foster City, Calif.). The twins had the
same genotype for all assessed markers. Uniparental diso-
my of chromosome 7 or 14 was ruled out by the presence
of informative markers at 7p21, 7q21, 7q35, and 14q23.
In conclusion, this additional evidence, as well as recent
data,1 corroborate our hypothesis that male pseudohermaph-
roditism, when accompanied by early growth retardation,
may not have a primarily or strictly genetic origin. How-
ever, we agree that available evidence is insufficient — and
is unlikely ever to be sufficient — to rule out the involvement
of all the known postzygotic or epigenetic mechanisms or
those that have yet to be discovered.
BERENICE B. MENDONCA, M.D.
ANA ELISA C. BILLERBECK, PH.D.
University of São Paulo
São Paulo CEP01060-970, Brazil
FRANCIS DE ZEGHER, M.D., PH.D.
University of Leuven
3000 Leuven, Belgium
francis.dezegher@uz.kuleuven.ac.be
1. Morel Y, Rey R, Teinturier C, et al. Aetiological diagnosis of male sex 
ambiguity: a collaborative study. Eur J Pediatr 2002;161:49-59.
Reactions to the Events of September 11
To the Editor: Schuster et al. (Nov. 15 issue)1 report an
increased incidence of distress after the events of Septem-
ber 11 and advise clinicians to be prepared to assist people
with trauma-related symptoms. Using national workload
data from the Department of Veterans Affairs, I compared
the average number of daily outpatient visits during the 19
working days before and after September 11 in different clin-
ical subgroups and geographic locations (excluding week-
ends, holidays, and September 11 itself ).
Veterans Affairs facilities in New York City had small,
nonsignificant (P>0.05) increases in the number of daily vis-
its for general medical care (6.1 percent) and mental health
care (5.0 percent), and more specifically for post-traumatic
stress disorder (4.3 percent) and substance abuse (5.4 per-
cent). Data from previous years show that these increases
were smaller than those for the same period in 2000 (which
had an 11.7 percent increase in mental health visits and a 21
percent increase in medical visits) but greater than those
observed in 1999 (which had an 11.5 percent decrease in
mental health visits and a 0 percent change in medical vis-
its). The small increases in the use of services in 2001 thus
differ little from those of previous years and probably re-
flect the fact that patients, clinicians, or both were returning
from August vacations. The 5.0 percent increase in the use
of mental health services in New York was slightly smaller
than the increases in Washington, D.C. (10.9 percent), oth-
er large northeastern cities (15.3 percent), Oklahoma City
(6.9 percent), and other large U.S. cities (10.1 percent).
Although the events of September 11 were profoundly
traumatic for those directly involved and clearly distressing
for others, they are not necessarily medically significant. I
found no substantial short-term change in the use of serv-
ices, even among more vulnerable patients with mental ill-
ness or post-traumatic stress disorder. Although we should
acknowledge our natural emotional reactions to tragic
events, we should not overly medicalize them without jus-
tification.
ROBERT ROSENHECK, M.D.
Veterans Affairs Northeast Program Evaluation Center
West Haven, CT 06516
robert.rosenheck@yale.edu
1. Schuster MA, Stein BD, Jaycox LH, et al. A national survey of stress 
reactions after the September 11, 2001, terrorist attacks. N Engl J Med 
2001;345:1507-12.
The authors reply:
To the Editor: We appreciate Dr. Rosenheck’s data on the
important issue of the use of health services in the 19 days
after the September 11 terrorist attacks. We look forward
to future research on the use of health services (as well as
on the unmet need for treatment) over longer periods and
in settings other than the Veterans Affairs system.
Our study found that many people across the United
States had stress reactions during the days after the attacks.
It is important for clinicians and others to be aware that
such reactions are common and may even occur in people
who are far from a disaster. Clinicians can reassure people
that their stress symptoms are typical and that they will of-
ten resolve without any intervention. Such information is
incorporated into most post-trauma mental health inter-
ventions.1,2 Clinicians can also inform their patients about
effective coping strategies and give additional attention to
those with persistent or particularly severe symptoms. Our
study found that most people were using coping strategies
that are considered healthy,2,3 such as talking with others,
turning to religion, participating in group activities, and
volunteering.
Many people’s reactions will dissipate over time and
without treatment, although ongoing threats, attacks, and
unrelated catastrophes may prolong the process for some.
We anticipate that a subgroup of people might have a harder
time recovering, because they were directly exposed to the
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attacks or because of their personal characteristics (e.g., a
history of mental health problems). 
MARK A. SCHUSTER, M.D., PH.D.
BRADLEY D. STEIN, M.D., M.P.H.
LISA H. JAYCOX, PH.D.
RAND
Santa Monica, CA 90407-2138
schuster@rand.org
1. Foa EB, Davidson JRT, Frances A, eds. The expert consensus guideline 
series: treatment of posttraumatic stress disorder. J Clin Psychiatry 1999;
60:Suppl 16.
2. Forster P. Nature and treatment of acute stress reactions. In: Austin LS, 
ed. Responding to disaster: a guide for mental health professionals. Wash-
ington, D.C.: American Psychiatric Press, 1992:25-51.
3. Norris FH. 50,000 Disaster victims speak: an empirical review of the 
empirical literature, 1981–2001. Bethesda, Md.: National Institutes of 
Health, September 2001.
Emergence of Macrolide Resistance during 
Treatment of Pneumococcal Pneumonia
To the Editor: The emergence of antibiotic resistance dur-
ing treatment for pneumococcal infection is exceedingly
rare.1 To our knowledge, there is no previous report of a
genetically characterized, antibiotic-resistant pneumococcal
mutant emerging during therapy and serving as the cause
of treatment failure.
A previously healthy 28-year-old man presented with a
five-day history of cough and dyspnea. He had hypoten-
sion, hypothermia, and rales in the right upper lung. His
white-cell count was 14,000 per cubic millimeter (28 per-
cent bands). Chest roentgenography showed infiltrates in
the right middle and upper lobe. The sputum contained
abundant gram-positive diplococci, and culture yielded
Streptococcus pneumoniae; blood cultures were negative.
Empirical therapy with 500 mg of azithromycin per day
Figure 1. The Macrolide-Binding Site of the Resistant Mutant.
The macrolide-binding site is depicted as a large cavity between the L22 protein (ribbon diagram on the right-hand side) and the
23S ribosomal RNA, near position A2058 (on the left-hand side). The insert of six amino acids encoded by the 18-bp tandem repeat
is shown as a green bar. The hairpin region of L22 comes within 15 Å of the 23S base A2058 (identified according to the Escherichia
coli numbering scheme); the peptide insert is about 22 Å from this region. This insertion is believed to alter the fit of macrolides
into the ribosomal pocket. To generate this figure, we aligned the gene for L22 from Streptococcus pneumoniae and Thermus
thermophilus, identifying the location of the six-residue repeat fragment, RTAHIT, after residue 102 in the resistant isolate. We then
mapped the location of this insert onto the published structure of L22 from T. thermophilus3 and performed a least-squares su-
perposition of L22 from T. thermophilus onto the structure of L22 from Haloarcula marismortui4 in the context of the 23S RNA
molecule.
A2058
Protein insert
15 Å
25 Å
22 Å
Arg88 Met86
Erythromycin
binding site
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intravenously was begun at admission, and the patient’s con-
dition improved rapidly. On the fourth day of treatment, his
condition suddenly deteriorated, and hypotension and hy-
pothermia again appeared. Roentgenography revealed ex-
tensive right-sided infiltrates and pleural effusion. Cultures
of bronchoalveolar-lavage and pleural fluids yielded pneu-
mococcus; blood cultures were negative. Ceftriaxone and
vancomycin were administered, but multiorgan failure de-
veloped, and the patient died. His relatives declined to
give permission for an autopsy.
The isolates of S. pneumoniae from the initial sputum
sample and from pleural fluid obtained at the time of re-
lapse were serotype 3 and were identical on BOX polymer-
ase chain reaction (BOX elements are interspersed repeti-
tive DNA sequences in S. pneumoniae) and ribotype
analysis.2 The initial isolate was fully susceptible to all an-
tibiotics tested, including penicillin (minimal inhibitory
concentration [MIC], <0.016 µg per milliliter), clinda-
mycin (MIC, 0.008 µg per milliliter), erythromycin
(MIC, 0.015 µg per milliliter), azithromycin (MIC, 0.008
µg per milliliter), and quinupristin–dalfopristin (MIC,
0.12 µg per milliliter). In contrast, the later isolate, al-
though still susceptible to penicillin and clindamycin, was
resistant to erythromycin, azithromycin, and quinupris-
tin–dalfopristin (MIC, 2 to 4 µg per milliliter). Neither
isolate contained erm(B) or mef (A),3 two determinants of
erythromycin resistance.
Genes encoding 23s ribosomal RNA and ribosomal
proteins involved in macrolide binding were sequenced.
The gene for ribosomal protein L22 in the macrolide-
resistant mutant contained an 18-bp tandem repeat that
was not present in the original isolate. This insertion
resulted in the duplication of six amino acids —
102KRTAHITRTAHITVA116 — adjacent to the macrolide-
binding site on the 23s RNA (Fig. 1). No other mutations
were identified.
Macrolides inhibit bacterial-protein translation by
inserting themselves into a pocket of the 23S ribosomal
subunit at the site of protein assembly. Most macrolide-
resistant pneumococci alter the macrolide-binding site
by erm(B)-encoded methylation of A2058 or exclude
macrolides by a mef (A)-encoded efflux pump.5 Mutations
that alter protein sequences in this pocket may, however,
cause macrolide resistance, as has been demonstrated
for ribosomal proteins L4 and L22.6,7 We hypothesize
that, in the mutant strain from this patient, the six-amino-
acid repeat in L22 disrupts the binding cavity by altering
the tertiary structure of the hairpin (Fig. 1). The mutation
occurred during therapy, causing a relapse that was fatal.
DANIEL M. MUSHER, M.D.
Veterans Affairs Medical Center
Houston, TX 77030
daniel.musher@med.va.gov
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VIRGINIA D. SHORTRIDGE, PH.D.
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